Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?  

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context of the COVID-19 pandemic. This schedule was approved in Europe based on modeling/simulation (, but the FDA rejected the every 6 week dosing in February 2020. 

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at Horizon Oncology Ctr
FDA Approves Merck’s KEYTRUDA (pembrolizumab...
Medical Oncologist at Kaiser Permanente
Has anyone noticed increased toxicity rates since ...
Sign in or Register to read more